OOIR: Observatory of International Research

Papers

(The H4-Index of Current Atherosclerosis Reports is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	91
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	90
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	85
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	73
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	67
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	60
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	60
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	58
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	57
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	57
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	56
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	50
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	50
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	48
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	47
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	46
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	45
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	43
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	43
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	40
The Emerging Specialty of Cardio-Rheumatology	38
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	38
Myeloid Cells in Abdominal Aortic Aneurysm	36
Inflammation in the Peri-ACS Period: Ready for Prime Time?	36
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	36

Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	35
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	34
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	32
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	32
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	32